Wegner RE, et al. - Because atypical bronchopulmonary carcinoid tumors are rare but have high recurrence rates after resection, researchers looked at adjuvant therapy predictors and outcome effects. For patients with resected stage I-III atypical carcinoid, they queried the National Cancer Database. In total, 533 patients were identified in stage I/II and 129 patients in stage III. Age, margins, comorbidity score, and lymph node ratio (LNR) were predictors for survival in stage I/II. LNR and more remote year of treatment were factors for stage III disease. This investigation exhibits no clear survival benefit, even in stage III disease, with adjuvant radiotherapy and/or chemotherapy. While this implies that adjuvant therapy should not be routinely delivered, it is still recommended for individualized judgment.